Sept. 30 Company Quick Takes: Lumos-NewLink, Simcere-JW, Ocugen-CanSino, Chamishi’s launch, and AbbVie-Allergan

Lumos finds public path

Rare disease company Lumos Pharma Inc. plans to go public via a reverse merger with NewLink Genetics Corp. (NASDAQ:NLNK). Set to own about 50% of the combined company are Lumos’ shareholders, which

Read the full 357 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE